Epigenomics News and Research

RSS

Curemark Founder delivers Industry Keynote address at Epigenomics Conference 2009

Curemark Founder and CEO Dr. Joan Fallon delivered the Industry Keynote address at the Third International Epigenomics, Sequencing 2009 Conference at Harvard Medical School on July 14th

24 Aug 2009

Gene expression patterns in cancer could aid early screening and prevention

Distinctive patterns of genes turned off - or left on - in healthy versus cancerous cells could enable early screening for many common cancers and maybe help avoid them, Medical College of Georgia scientists say.

28 Jul 2009

Breakthrough method for sequencing-based methylation profiling

Bioengineers at UC San Diego have developed a breakthrough method for sequencing-based methylation profiling, which could help fuel personalized regenerative medicine and even lead to more efficient and cost-effective methods for studying certain diseases.

23 Apr 2009

B-cell clones as early markers for chronic lymphocytic leukemia

Testing of blood specimens may detect abnormal white blood cells in patients years before the chronic form of lymphocytic leukemia (CLL) develops, according to research published in the current issue of the New England Journal of Medicine.

22 Feb 2009

Discovery of new class of non-protein coding genes in mammals with key functions

A research team at the Broad Institute of Harvard and MIT and Beth Israel Deaconess Medical Center has uncovered a vast new class of previously unrecognized mammalian genes that do not encode proteins, but instead function as long RNA molecules.

2 Feb 2009

Roche NimbleGen microarray technology enables highest-resolution map of human genome copy number variation

Roche NimbleGen's CGH microarray platform was used to generate the highest-resolution map of human genome copy number variation.

23 Jan 2009

Antineoplaston treatment for gliomas granted orphan drug designation by FDA

The Burzynski Research Institute, Inc. (BRI) has announced that its antineoplaston A10 and antineoplaston AS2-1 therapy (ANP) has been granted orphan drug designation by the U.S. Food and Drug Administration ("FDA") for the treatment of gliomas. It is estimated that in 2008 more than 21,000 men and women in the U.S. will be diagnosed with this type of cancer, with prevalence estimated at approximately 84,000 cases.

2 Dec 2008